Long-term clinical course and histopathologic scoring in acute crescentic glomerulonephritis
Related Experiment Video
Updated: Nov 2, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
D Bach1, B C Klein, B Grabensee
1Department of Nephrology, Heinrich-Heine University Düsseldorf Germany.
Insights
Early diagnosis of rapidly progressive glomerulonephritis (RPGN) using histopathology is crucial for predicting kidney prognosis and guiding treatment. This approach aids in managing end-stage renal failure (ESRD) effectively.
Area of Science:
- Nephrology
- Immunopathology
- Renal Medicine
Background:
- Acute crescentic glomerulonephritis, or rapidly progressive glomerulonephritis (RPGN), can rapidly lead to end-stage renal failure (ESRF) if untreated or misdiagnosed.
- Histologically, RPGN involves inflammatory cell accumulation and epithelial cell proliferation within glomeruli.
- Type III immunopathogenic RPGN, often without immune deposits, can signify systemic vasculitis like polyarteritis or Wegener's granulomatosis.
Purpose of the Study:
- To investigate the long-term outcomes of 75 patients diagnosed with acute crescentic glomerulonephritis.
- To evaluate the utility of early histopathologic diagnosis using activity and chronicity scoring systems in predicting renal prognosis.
- To assess the role of differentiated immunosuppressive therapy and plasmapheresis in managing RPGN.
Main Methods:
- Retrospective analysis of 75 patients with acute crescentic glomerulonephritis.
- Histopathologic evaluation using an activity and chronicity score system.
- Correlation of histopathologic findings with clinical data, renal function, and long-term outcomes.
Main Results:
- Early histopathologic diagnosis via activity and chronicity scoring is a valuable predictor of renal prognosis.
- This diagnostic approach supports tailored immunosuppressive therapy decisions.
- No significant therapeutic advantage was demonstrated for adding plasmapheresis to immunosuppressive therapy.
Conclusions:
- Early, detailed histopathologic assessment is essential for managing rapidly progressive glomerulonephritis (RPGN).
- Histopathology aids in predicting renal prognosis and guiding individualized immunosuppressive treatment strategies.
- Plasmapheresis did not show additional benefit in this patient cohort.
Abstract:
If nontreated or misdiagnosed, acute crescentic glomerulonephritis, clinically defined as rapidly progressive glomerulonephritis (RPGN), may led to end-stage renal failure (ESRD) within a short time. Histologically, it is characterized by accumulation of inflammatory cells in combination with proliferation of epithelial cells in the glomerulus. According to the proposed immunopathogenic classification by Couser (7), predominantly the immunopathogenic type III without immune deposits often represents the renal manifestation of a systemic vasculitic disease, for example, polyarteriitis or Wegener's granulomatosis. Having investigated 75 patients with acute crescentic glomerulonephritis in respect to their long-term results, we conclude that an early histopathologic diagnosis by using an activity and chronicity score system may not only be a predictor for renal prognosis but also be a valid supposition for differentiated immunosuppressive therapy in supplement to the clinical data on renal function. A therapeutic advantage of a plasmapheresis therapy additionally to the immunosuppressive therapy could not be proven.
Related Concept Videos
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome I : Introduction
Acute Kidney Injury I: Introduction
Acute Pyelonephritis I: Introduction